PharmPK Discussion - What is a possible fate of a protein/peptide drug in vivo

PharmPK Discussion List Archive Index page

On 4 Nov 2004 at 12:29:38, Keguan.Chen.aaa.mdsps.com sent the message


Dear all,
We are doing immunogenicity tests for the biological therapeutic drugs,
such as recombinant proteins, peptides and humanized Abs. I would like
to
know what are the in vivo fates of pegylated* or non pegylated
protein/peptide drugs.  Are there any
books or published papers discussing details of the processes? If the
fragments of protein/peptide drug are not immunogenic, does the immune
system still process the fragments through APC/T cells?
Thanks a lot,
KC
*. Pegylation is a technology designed to prolong or improve the
effectiveness of pharmaceutical products. Conjugation of protein/peptide
drug to polyethylene glycol (PEG) has shown potential beneficial
effects,
such as increasing biovailability, increasing plasma half-lives,
decreasing immunogenecity, reducing proteolysis, and enhancing
solubility
and stability.   Several pegylated-drugs have been on the market.

Back to the Top

On 4 Nov 2004 at 12:38:21, "Milesi-halle, Alessandra " (MilesihalleAlessandr.aaa.uams.edu) sent the message


This paper may be helpful to you:
Pegylation: a novel process for modifying pharmacokinetics.
Harris JM, Martin NE, Modi M.
Clin Pharmacokinet. 2001;40(7):539-51.
Regards,
Alessandra Milesi-Halle, M.D.
Department of Pharmacology and Toxicology
University of Arkansas for Medical Sciences
4301 West Markham, slot 611
Little Rock, Arkansas 72205
Phone: (501)686-6551
Fax: (501)686-5521
MilesihalleAlessandr.-at-.uams.edu

Back to the Top

Want to post a follow-up message on this topic? If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "What is a possible fate of a protein/peptide drug in vivo" as the subject

PharmPK Discussion List Archive Index page